Paracrine Effects of Bone Marrow Mononuclear Cells in Survival and Cytokine Expression after 90% Partial Hepatectomy

• Published in: Stem cells international Vol. 2017; no. 2017; pp. 1 - 8
• Main Authors: Silveira, Themis Reverbel da, Osvaldt, Alessandro, López, Mónica Luján, Uribe-Cruz, Carolina, Kieling, Carlos Oscar, Matte, Ursula
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2017; Hindawi; John Wiley & Sons, Inc; Hindawi Limited; Wiley
• Subjects: Apoptosis; Bone marrow; Bone marrow cells; Care and treatment; Cytokines; Gastroenterology; Gene expression; Glucose; Hepatectomy; Laboratories; Liver; Liver failure; Rodents; United States > US
• ISSN: 1687-966X; 1687-9678; 1687-9678
• DOI: 10.1155/2017/5270527

Acute liver failure is a complex and fatal disease. Cell-based therapies are a promising alternative therapeutic approach for liver failure due to relatively simple technique and lower cost. The use of semipermeable microcapsules has become an interesting tool for evaluating paracrine effects in vivo. In this study, we aimed to assess the paracrine effects of bone marrow mononuclear cells (BMMC) encapsulated in sodium alginate to treat acute liver failure in an animal model of 90% partial hepatectomy (90% PH). Encapsulated BMMC were able to increase 10-day survival without enhancing liver regeneration markers. Gene expression of Il-6 and Il-10 in the remnant liver was markedly reduced at 6 h after 90% PH in animals receiving encapsulated BMMC compared to controls. This difference, however, was neither reflected by changes in the number of CD68+ cells nor by serum levels of IL6. On the other hand, treated animals presented increased caspase activity and gene expression in the liver. Taken together, these results suggest that BMMC regulate immune response and promote apoptosis in the liver after 90% PH by paracrine factors. These changes ultimately may be related to the higher survival observed in treated animals, suggesting that BMMC may be a promising alternative to treat acute liver failure.